David Geffen School of Medicine at UCLA, 2020 Santa Monica Blvd, Suite 600, Los Angeles, CA, 90404, USA.
Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Target Oncol. 2017 Dec;12(6):775-785. doi: 10.1007/s11523-017-0530-5.
This phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and gedatolisib (PF-05212384; arms C, D) in combination with the MEK inhibitor PD-0325901 (arm A, D) or irinotecan (arm B, C) in patients with advanced solid tumors.
Primary endpoint was dose-limiting toxicity with each combination. Secondary endpoints included safety, pharmacokinetics and preliminary antitumor activity.
Dose escalation followed a 3 + 3 design in arm C and a zone-based design in arm D.
The PF-04691502 combination arms were closed prematurely due to low tolerability, and the maximum tolerated doses (MTDs) were not determined for either arm. The MTD for the combination of gedatolisib with irinotecan 180 mg/m was estimated to be 110 mg weekly and for the combination with PD-0325901 was not reached at the highest dose evaluated (gedatolisib 154 mg weekly). Plasma concentrations of gedatolisib were generally similar across dose groups in arm C (with irinotecan) and arm D (with PD-0325901). Frequent dose delays or dose reductions were required for both combinations, potentially preventing sustained therapeutic drug concentrations. Gedatolisib plus irinotecan produced a response rate of ~5% and clinical benefit in 16% of patients with advanced colorectal cancer (progression-free survival, 2.8 months). Preliminary evidence of clinical activity was observed with gedatolisib plus PD-0325901 in patients with ovarian cancer (three partial responses, n = 5) or endometrial cancer (one partial response, n = 1) and KRAS mutations.
Further evaluations of gedatolisib are warranted in patients with advanced solid malignancies.
这项 I 期、四臂、开放性研究(NCT01347866)评估了 PI3K/mTOR 抑制剂 PF-04691502(臂 A、B)和 gedatolisib(PF-05212384;臂 C、D)与 MEK 抑制剂 PD-0325901(臂 A、D)或伊立替康(臂 B、C)联合用于晚期实体瘤患者。
各组合的主要终点是剂量限制毒性。次要终点包括安全性、药代动力学和初步抗肿瘤活性。
在臂 C 中采用 3+3 设计,在臂 D 中采用基于区域的设计进行剂量递增。
PF-04691502 联合用药组因耐受性低而提前关闭,无法确定任一组的最大耐受剂量(MTD)。gedatolisib 联合伊立替康 180mg/m 的最大耐受剂量估计为每周 110mg,而联合 PD-0325901 的最高剂量(每周 154mg gedatolisib)尚未达到。在臂 C(联合伊立替康)和臂 D(联合 PD-0325901)中,gedatolisib 的血浆浓度在各剂量组中通常相似。两种联合用药均需要频繁延迟或减少剂量,可能会阻止持续的治疗药物浓度。gedatolisib 联合伊立替康在晚期结直肠癌患者中产生了约 5%的缓解率和 16%的临床获益(无进展生存期,2.8 个月)。在卵巢癌(5 例患者中有 3 例部分缓解,n=5)或子宫内膜癌(1 例部分缓解,n=1)和 KRAS 突变患者中观察到 gedatolisib 联合 PD-0325901 的初步临床活性证据。
需要进一步评估 gedatolisib 在晚期实体恶性肿瘤患者中的应用。